Part I – The Rise: China’s Biotech Shift From Generics to Global Deal Maker

China’s drug industry has moved beyond copycat medicines into a pipeline of first-/best-in-class candidates, reshaping how—and where—Big Pharma sources innovation. This shift is visible in the rise of oncology and cardiometabolic pipelines, the expansion of incubators and R&D hubs in Shanghai and Beijing, and a surge of licensing deals that increasingly flow from China to the West. Regulatory reforms, faster trial approvals, and lower development costs have positioned Chinese companies as credible global partners, while Big Pharma’s search for new assets amid looming patent cliffs has accelerated the trend. The opportunity is large, the geopolitics are volatile, and the next battlegrounds are oncology and metabolic disease.

Why Patent Cliffs and Cash Reserves Are Steering Deals East

• Pipelines and approvals are tilting global. Morgan Stanley projects drugs originating in China could generate $34B by 2030 and $220B by 2040; by then, ~35% of FDA approvals could stem from China-origin assets (vs. ~5% today).
  
• Licensing dollars are flowing east-to-west. China accounted for ~32% of global out-licensing deal value in early 2025, up from ~21% in 2023–24—an abrupt change in where pipelines get replenished.
  
• Big Pharma has the cash—and the need. Patent cliffs loom and large pharmas have ~$1.3T of M&A “firepower,” but are favoring targeted licensing over megamergers. 

These shifts highlight a deeper redistribution of innovation and capital flows in biotech. If Morgan Stanley’s forecast proves accurate, China-origin drugs could account for over a third of FDA approvals and generate $220 billion annually by 2040—a level that would put Chinese innovators on par with established U.S. and European players in terms of market impact. On the deal-making side, nearly one-third of global out-licensing value in early 2025 involved Chinese assets, marking a rapid reversal of the old east-to-west model where China mainly imported.

For multinational companies, the timing is critical: roughly $115 billion in revenue could evaporate by 2035 as patents expire, leaving gaps in portfolios that licensing can help plug. With almost $1.3 trillion earmarked for transactions, big pharmas are now redirecting capital from headline mergers toward more flexible partnerships in China. This suggests a new operating logic: pipelines will be increasingly built through modular licensing from emerging hubs like China, rather than through consolidation among traditional incumbents.

How Regulatory Reforms and Lower Trial Costs Put China on the Global Map

Regulatory and cost advantages. Over the past decade, China has overhauled its regulatory framework to align more closely with the U.S. FDA and the European Medicines Agency (EMA), which has cut duplication and reduced barriers for cross-border filings. Streamlined clinical trial approvals, acceptance of foreign clinical data, and priority review pathways have all contributed to faster timelines. 

At the same time, the relative affordability of running studies in China—due to lower patient recruitment costs, large treatment-naïve populations, and a dense network of trial sites—means that programs can generate robust human data for a fraction of what it would cost in Western markets. This aligns with a broader surge in clinical trial activity—China registered 16,612 trials in 2023, compared with just 9,100 in the U.S., with antibodies and antibody–drug conjugates driving much of the growth. While concerns about trial quality persist, reforms such as mandatory preregistration and institutional review board (IRB) oversight have strengthened confidence. Taken

This combination has enabled domestic companies to demonstrate proof of concept earlier and position themselves as credible partners for global firms. Recent examples illustrate the effect: long-acting respiratory biologics were able to generate pivotal Phase II data in China before being licensed to global players, while oncology bispecific antibodies advanced quickly into multinational portfolios through large upfront licensing deals. Together, these regulatory and cost dynamics explain why China has become an attractive source of de-risked assets that can be integrated into Western pipelines without the lengthy and expensive early-stage burden.

Why Portfolio Deals and Equity Stakes Are the New Normal

• GSK–Hengrui ($500M upfront, up to $12B milestones, 12 programs): Instead of paying for one promising drug, GSK secured access to an entire portfolio spanning respiratory, immunology, and oncology. This “platform-style” deal spreads scientific and regulatory risk across multiple programs, gives GSK early visibility into Hengrui’s pipeline, and ensures a flow of assets that can be advanced globally. It signals a shift from single-asset licensing to portfolio partnerships, reflecting how Big Pharma now views Chinese biotechs not just as one-off innovators but as ongoing sources of discovery.
• Pfizer–3SBio ($1.25B upfront, up to $4.8B milestones + $100M equity): By taking both licensing rights and an equity stake, Pfizer tied itself into the long-term success of 3SBio’s PD-1/VEGF bispecific. The deal shows how Big Pharma is pairing Western commercialization scale with China-generated clinical data, while also signaling deeper strategic alignment rather than a one-off transaction.

• AstraZeneca–CSPC ($100M upfront, up to $1.92B milestones): By licensing a preclinical Lp(a) disruptor, AstraZeneca showed willingness to bet early on China-origin cardiometabolic science. The deal reflects Big Pharma’s appetite for very early-stage assets from China, signaling trust in local discovery platforms and a push to secure optionality in high-growth disease areas.

A New Operating Logic for Global Biopharma

These shifts establish China not just as a manufacturing hub or secondary market but as a central force shaping global drug pipelines. Chinese innovators drive portfolios that Big Pharma now assembles through modular licensing and cross-border partnerships instead of consolidation at home. Oncology and cardiometabolic programs provide early proof points, yet the broader lesson shows that scientific risk now spreads across geographies, capital flows in new directions, and the traditional innovation hierarchy flattens. Multinational companies must source assets from China and adapt to new pricing, regulatory, and competitive benchmarks that reset the global standard for drug development and commercialization.

Author

Bernice Lottering